slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Maarten A. Vink, Maurits T. Dirksen, Maarten J. Suttorp, Jan G.P. PowerPoint Presentation
Download Presentation
Maarten A. Vink, Maurits T. Dirksen, Maarten J. Suttorp, Jan G.P.

Loading in 2 Seconds...

play fullscreen
1 / 25

Maarten A. Vink, Maurits T. Dirksen, Maarten J. Suttorp, Jan G.P. - PowerPoint PPT Presentation


  • 182 Views
  • Uploaded on

Five year clinical follow-up of the PASSION -trial Five Year Follow-up after Primary PCI with a Pa clitaxel-Eluting S tent versus a Bare-Metal Stent in Acute S T-Elevation Myocardial Infarct ion.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Maarten A. Vink, Maurits T. Dirksen, Maarten J. Suttorp, Jan G.P.' - anahid


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Five year clinical follow-up of the PASSION-trialFive Year Follow-up after Primary PCI with a Paclitaxel-Eluting Stent versus a Bare-Metal Stent in Acute ST-Elevation Myocardial Infarction

Maarten A. Vink, Maurits T. Dirksen, Maarten J. Suttorp, Jan G.P. Tijssen, GertJan Laarman

on behalf of the PASSION investigators

OLVG Hospital,

Amsterdam, The Netherlands

ACC/i2 2010 Late-breaking clinical trial session, March 16, 2010

disclosure information
Disclosure information

Maarten A. Vink, M.D.:

Nothing to disclose

background
Background

DES in primary PCI

  • Several RCTs showed a variable reduction in the need for repeat revascularization of infarct-related artery in favour of DES.
  • No differences in survival rates or recurrent MI

Laarman et al N Engl J Med 2006; Kastrati et al Eur Heart J 2007;

Stone et al N Engl J Med 2009

background4
Background

DES and stent thrombosis

  • HORIZONS-AMI showed similar rates of stent thrombosis with DES and BMS at one year1.
  • However, concern has arisen about the occurrence of (very) late stent thrombosis after implantation of DES2.
  • Available data suggest a higher rate of (very) late stent thrombosisafter the use of DES in primary PCI, compared to stenting for stable angina3.

1Stone et al N Engl J Med 2009; 2Pfisterer et al J Am Coll Cardiol 2006;

3Leibundgut e al Am Heart J 2009;

background5
Background

DES and stent thrombosis in primary PCI

  • In the absence of long-term outcome of RCTs, this issue remains unresolved.
  • Therefore, guidelines do not uniformly support the use of DES in primary PCI for STEMI.
      • ACC/AHA 2009 IIa B indication
      • ESC 2008 not defined
passion 5 year clinical follow up
PASSION 5-year clinical follow-up
  • Clinical follow-up at 5 years
  • To elucidate a possible sustained benefit of DES in the occurrence of MACE
  • To address the concern of late and very late stent thrombosis
passion trial
PASSION-trial
  • Prospective, two-center, randomized, single-blind trial
  • Enrollment March 2003 - December 2004
    • OLVG Hospital, Amsterdam, The Netherlands
    • St. Antonius Hospital, Nieuwegein, The Netherlands
  • 619 consecutive patients with STEMI, eligible for primary PCI with stenting
  • Representative of real world population owing to limited exclusion criteria
  • No routine angiographic follow-up
  • Clinical follow-up at: 6, 12, 24, and 60 months
limited exclusion criteria
Limited exclusion criteria
  • Cardiogenic shock prior to randomization
  • Mechanical ventilation
procedure
Procedure
  • Stent diameter and length decided before randomization
  • Randomization to:

paclitaxel-eluting stent (Taxus/Express2) or

bare metal stent (Express2 or Liberté)

  • Additional stents according to assigned stent type
  • Thrombus aspiration and direct stenting at the discretion of the operator
concomitant medication
Concomitant medication
  • GP IIb/IIIa receptor blocker at the discretion of the operator
  • Post-PCI:
    • Clopidogrel 300 mg, followed by 75 mg od for at least 6 months
    • Aspirin 100 to 500 mg, followed by 80-100 mg od indefinitely
clinical outcome at 1 year
Clinical Outcome at 1 year

Laarman et al N Engl J Med 2006

long term follow up
Long-term Follow-up
  • Complete follow-up available at 5 years:
      • vital status: 98.5% (9 patients lost to FUP)
      • clinical events: 95.8%
stent thrombosis
Stent Thrombosis

Incidences were estimated from the Kaplan-Meier curves

late and very late stent thrombosis
Late and Very Late Stent Thrombosis

Incidences were estimated from the Kaplan-Meier curves

conclusions
Conclusions

PASSION 5-year follow-up

PES compared to BMS in primary PCI

  • The PASSION-trial is the first RCT to report very long-term follow-up.
  • No significant difference in the occurrence of the composite endpoint of cardiac death, recurrent MI, or TLR
  • No significant differences in the occurrence of individual major adverse cardiac events
conclusions23
Conclusions

PASSION 5-year follow-up

PES compared to BMS in primary PCI

  • 5-year follow-up of the PASSION-trial confirms small risk of (very) late stent thrombosis.
  • Comparable incidence of definite or probable stent thrombosis
  • However, the rate of definite stent thrombosis in the PES-group was two-fold as compared to the BMS-group (P = 0.20).
conclusions24
Conclusions

DES in primary PCI for STEMI

  • The risk of stent thrombosis appears to persist for several years after stent implantation.
  • We have to outweigh the possible advantage of DES in TLR against the potential risk of (very) late stent thrombosis.
thanks to
Thanks to:

The PASSION Investigators

MT Dirksen, MJ Suttorp, JGP Tijssen, J van Etten,T Slagboom, M Patterson, F Kiemeneij, GJ Laarman

And to all patients and co-workers of the PASSION trial at

OLVG Hospital, Amsterdam

St. Antonius Hospital, Nieuwegein